-
1 Comment
Nemaura Medical Inc is currently in a long term uptrend where the price is trading 31.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Nemaura Medical Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 225.1% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 186.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Nemaura Medical Inc gets an overall score of 2/5.
Exchange | PINK |
---|---|
CurrencyCode | USD |
ISIN | US6404422080 |
Sector | Healthcare |
Industry | Medical Devices |
Beta | -100.9 |
---|---|
Market Cap | 8K |
PE Ratio | None |
Target Price | 1.5 |
Dividend Yield | None |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NMRD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025